Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donia Skanji

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Statistics in Medicine|November 25, 2025
Bayesian Prediction of Event Times Using Mixture Model for Blinded Randomized Controlled TrialsJingyan Fu, Dan Zhao, Donia Skanji, et al.
Pharmaceutical Statistics|July 2, 2024
Futility Interim Analysis Based on Probability of Success Using a Surrogate EndpointRonan Fougeray, Loïck Vidot, Marco Ratta, et al.
Statistical Methods in Medical Research|January 24, 2024
A comparison of model-free phase I dose escalation designs for dual-agent combination therapiesHelen Barnett, Matthew George, Donia Skanji, et al.
Statistics in Medicine|January 23, 2026
Dual-Criterion Approach Incorporating Historical Information to Seek Accelerated Approval With Application in Time-to-Event Group Sequential TrialsMarco Ratta, Gaëlle Saint-Hilary, Valentine Barboux, et al.
Future Oncology (London, England)|February 23, 2025
NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: an open-label, phase II trial designMasafumi Ikeda, Takuji Okusaka, Makoto Ueno, et al.
Pharmaceutical Statistics|April 19, 2026
Integrating Preclinical Insights for Adaptive Dose Escalation in Phase I Oncology TrialsHelen Barnett, Melanie Guhl, Fulvio Di Stefano, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 5, 2020
Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGSJosep Tabernero, Maria Alsina, Kohei Shitara, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Statistics in Medicine|November 25, 2025
Bayesian Prediction of Event Times Using Mixture Model for Blinded Randomized Controlled TrialsJingyan Fu, Dan Zhao, Donia Skanji, et al.
Pharmaceutical Statistics|July 2, 2024
Futility Interim Analysis Based on Probability of Success Using a Surrogate EndpointRonan Fougeray, Loïck Vidot, Marco Ratta, et al.
Statistical Methods in Medical Research|January 24, 2024
A comparison of model-free phase I dose escalation designs for dual-agent combination therapiesHelen Barnett, Matthew George, Donia Skanji, et al.
Statistics in Medicine|January 23, 2026
Dual-Criterion Approach Incorporating Historical Information to Seek Accelerated Approval With Application in Time-to-Event Group Sequential TrialsMarco Ratta, Gaëlle Saint-Hilary, Valentine Barboux, et al.
Future Oncology (London, England)|February 23, 2025
NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: an open-label, phase II trial designMasafumi Ikeda, Takuji Okusaka, Makoto Ueno, et al.
Pharmaceutical Statistics|April 19, 2026
Integrating Preclinical Insights for Adaptive Dose Escalation in Phase I Oncology TrialsHelen Barnett, Melanie Guhl, Fulvio Di Stefano, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 5, 2020
Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGSJosep Tabernero, Maria Alsina, Kohei Shitara, et al.
Pageof 1